AI-Driven Retinal Screening Device Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global AI-Driven Retinal Screening Device Market Trends and Insights

Rising Diabetes Burden and Undiagnosed Retinopathy Risk

The AI-driven retinal screening device market is being supported by a large and persistent pool of people who need regular eye screening but are still outside formal care pathways. In 2024, 589 million adults worldwide lived with diabetes, and 42.80% of them were undiagnosed, which left a very large population exposed to delayed retinal disease detection. A 2025 review covering 21 countries reported pooled diabetic retinopathy prevalence of 28.40% among people with diabetes, which supports the view that the screening burden is structurally large and long-lasting.^{[1]IDF diabetes Atlas: A worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive} Because 81% of people with diabetes live in low- and middle-income countries, the AI-driven retinal screening device market is not tightly tied to premium device affordability and is instead pushed by the need for scale and lower cost delivery. This pattern supports software-led platforms and portable screening workflows, since they can reach primary care sites and underserved populations faster than specialist-centered service models.

Shortage of Ophthalmologists and Specialist Bottlenecks

The AI-driven retinal screening device market is also advancing because the eye care workforce remains too limited and too unevenly distributed to support specialist-led screening at the needed scale. A 2026 workforce estimate placed the global supply at 275,551 ophthalmologists, or 34 per million people, with only 6 countries accounting for half of the total supply.^{[2]The global eye care workforce: 2023 estimates across ophthalmologists, optometrists, and allied personnel} India was reported to have only 1 ophthalmologist for every 65,000 people, which shows why demand is moving toward triage and screening models that do not depend on large specialist teams. The same supply gap appears in other regions, and published research has shown that even high-income countries face large future workforce requirements to maintain access standards. This makes AI screening less of an optional tool and more of a capacity substitute that helps referral networks absorb rising diabetes-related eye disease volumes.

Shift Toward Point-of-Care and Primary Care Screening

The AI-driven retinal screening device market is gaining speed as retinal screening moves closer to the patient and away from specialist-only settings. In April 2024, the FDA cleared AEYE-DS for use with the Optomed Aurora handheld camera, which marked the first autonomous AI retinal screening clearance for a handheld device and widened the range of care settings where screening can take place. A 2026 study in the Johns Hopkins primary care system found that autonomous AI diabetic retinopathy screening increased subsequent presentation to eye care among at-risk patients. That result matters because it shows that the value of screening AI is not limited to image interpretation; it also improves follow-through into treatment pathways. As the AI-driven retinal screening device market expands in primary and preventive care, vendors with portable form factors and simple workflows are likely to benefit most.

Cloud Integration and Teleophthalmology Workflow Adoption

The AI-driven retinal screening device market is also being shaped by the growing role of cloud delivery, since remote workflows depend on fast image transfer, structured reporting, and system interoperability. Remidio Connect links handheld retinal imaging with EMR systems through HL7 messaging and returns graded results into clinical workflows, which shows how cloud delivery can support distributed screening programs. The 2025 HERMES trial reported that teleophthalmology reduced unnecessary urgent hospital referrals when compared with standard community optometry pathways. A 2026 AAAI publication also described a cloud-hosted framework for multi-disease retinal screening that fits teleophthalmology and EMR workflows. This supports the position of vendors that can embed retinal AI inside referral systems, reading networks, and hospital information flows instead of selling stand-alone diagnostic tools.

Data Privacy, Model Governance, and Cross-Border Data Restrictions

The AI-driven retinal screening device market faces a meaningful restraint from tightening data governance rules across major healthcare systems. The European Health Data Space Regulation, published in March 2025, added new secondary-use governance obligations that interact with existing GDPR standards and complicate cross-border handling of health imaging data. China also introduced YY/T 1949-2024, its first industry-specific dataset standard for diabetic retinopathy fundus images, which signaled a more formal approach to training data quality and validation. German guidance issued in 2025 further reinforced the view that retinal imaging data often require stronger protection than simple pseudonymization workflows can provide. These overlapping rules raise compliance costs and slow model transfer across regions, which gives larger vendors a clearer advantage in the AI-driven retinal screening device market.

Reimbursement Fragmentation Across Care Settings

The AI-driven retinal screening device market is also constrained by uneven reimbursement, especially when screening expands beyond well-funded health systems. Coverage for remote diabetic retinopathy screening codes declined significantly, and the decline was linked to unequal access across patient groups. A 2025 policy review found that AI reimbursement in the United States healthcare remained concentrated in affluent urban settings and academic medical centers. Regional reimbursement variation also makes it harder for large providers to deploy a uniform enterprise model across multiple sites. This keeps rollout slower in rural clinics, safety-net settings, and smaller practices, even where the clinical need for automated screening is strongest.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Software Economics Anchor Platform Margins

Software held 55.16% of the AI-driven retinal screening device market share in 2025, while services are forecast to grow at 21.98% CAGR through 2031. That pattern shows where commercial value is concentrating, since recurring algorithm access, workflow integration, cloud hosting, and support contracts carry more durable revenue than device shipments alone. The AI-driven retinal screening device market is therefore moving toward platform economics where software becomes the main value layer, and hardware becomes the access point for image capture. Hardware still matters because image quality remains the base input for any screening system, but its pricing power is under pressure as more vendors seek compatibility across multi-brand camera fleets.

This balance also explains why workflow depth now matters more than stand-alone diagnostic performance. Vendors that can connect retinal screening outputs into EMR, referral, and teleophthalmology systems are in a stronger position to hold renewals and expand accounts over time. The AI-driven retinal screening device industry is, therefore, rewarding platforms that can manage operational tasks around the algorithm, not just the algorithm itself. Services should continue to rise because hospitals and health systems increasingly require onboarding, validation support, training, and post-market monitoring as part of procurement. That trend favors vendors that can package clinical, technical, and regulatory support together under longer-term contracts.

By Technology: Fundus AI Leads, Multi-Modal Accelerates

Fundus image-based AI held 56.18% share in 2025, while multi-modal AI is forecast to grow at 24.15% CAGR through 2031. Fundus-based systems led early adoption because they aligned with lower-cost non-mydriatic cameras, simpler primary care workflows, and the first wave of autonomous regulatory clearances. The AI-driven retinal screening device market has therefore built its initial scale on technologies that can be deployed without the cost and workflow demands of OCT-heavy pathways. Multi-modal AI is now expanding faster because providers want broader single-encounter screening that can assess diabetic retinopathy, age-related macular degeneration, and glaucoma from paired inputs.

Peer-reviewed research from 2025 showed that models combining fundus photography and OCT improved performance across multiple retinal conditions when compared with single-modality systems. Another 2025 study reported 93.52% sensitivity and 95.00% specificity for a hybrid glaucoma screening model based on fundus images, which supports continued progress toward broader clinical use.^{[3]A hybrid multi model artificial intelligence approach for glaucoma screening using fundus images} OCT-based AI, machine learning, deep learning, and natural language processing still serve narrower workflow roles, but their relevance rises as the AI-driven retinal screening device market moves from single-disease screening to more integrated retinal assessment. The AI-driven retinal screening device industry is likely to see more value shift toward technology stacks that support multi-disease decision support rather than narrow single-indication tools.

By Deployment: Cloud-Based Dominance Reflects Platform Lock-In Economics

Cloud-based deployment held 63.89% share in 2025 and was also the fastest-growing deployment mode in the AI-driven retinal screening device market. This indicates that market expansion is not waiting for a future cloud transition, because that shift is already well advanced in commercial practice. Cloud delivery helps vendors push software updates, new pathology modules, and compliance changes across connected systems without relying on manual site-by-site updates. It also supports teleophthalmology, distributed screening, and enterprise contracting models that depend on centralized management and reporting.

On-premise deployment remains relevant where data localization, hospital IT rules, or cross-border transfer concerns limit external cloud use. Those conditions are especially important in some public hospital settings in China and in parts of Europe where data protection reviews can slow cloud approvals. Even so, published evidence from 2026 showed that cloud-hosted multi-disease retinal AI can be deployed in community and primary care settings with strong clinician and patient acceptance. The AI-driven retinal screening device market continues to favor vendors that can deliver secure cloud orchestration at scale while still supporting restricted environments when needed. This deployment structure also stretches vendor relationships beyond the life of any single imaging device, since value becomes linked to throughput, reporting, and referral management.

By Application: Diabetic Retinopathy Sets the Standard, AMD Gains Momentum

Diabetic retinopathy captured 43.18% of the AI-driven retinal screening device market size in 2025, while age-related macular degeneration is forecast to grow at 22.39% CAGR through 2031. Diabetic retinopathy led the way because it was the first major indication to gain autonomous AI commercial traction, and it aligns with large diabetes populations, regular screening needs, and clearer reimbursement pathways. The AI-driven retinal screening device market has therefore built its first strong revenue base around diabetic eye disease, where clinical burden, payer interest, and workflow standardization already overlap. AMD is growing faster because aging populations in North America, Europe, and East Asia are increasing demand for earlier retinal disease detection and follow-up support.

Glaucoma is also becoming more relevant as model performance improves and multi-modal datasets become more available. Research published in 2025 also showed that multi-disease frameworks can classify many distinct fundus conditions in a single encounter, which supports expansion into cataract-related screening, hypertensive retinopathy, pathological myopia, and retinal vein occlusion. The pace of expansion outside diabetic retinopathy will still depend on how quickly additional applications achieve regulatory acceptance and fit into reimbursable care pathways. That means the AI-driven retinal screening device market should keep its largest revenue pool in diabetic retinopathy for now, even as growth broadens into other retinal conditions.

By End User: Hospitals Anchor Volume, Clinics Drive Growth

Hospitals held 41.18% share in 2025, while ophthalmology clinics are forecast to grow at 23.44% CAGR through 2031. Hospitals led early deployment because they had stronger procurement capacity, larger diabetes and endocrinology patient flows, and higher tolerance for introducing first-generation AI systems into formal clinical pathways. This gave hospitals a central role in validating the AI-driven retinal screening device market and proving workflow reliability for wider adoption. Ophthalmology clinics are now growing faster because they are absorbing AI-positive referrals from primary care settings and using AI tools to handle more patients without matching increases in specialist staffing.

Mobile clinics and rural camps are also becoming more important, where specialist access and clinic density remain limited. Portable systems such as Remidio's handheld retinal imaging platform support that expansion by bringing image capture and referral triage closer to underserved populations. Diagnostic centers and academic institutions play supporting roles, since one group delivers throughput and the other generates the evidence base for extended clinical use. Telemedicine providers have also become more visible buyers in the AI-driven retinal screening device market because asynchronous retinal reading and cloud-based review create scalable service models. This broadening end-user mix shows that market growth is no longer tied only to hospital purchasing cycles.

Geography Analysis

North America held 43.18% of the AI-driven retinal screening device market share in 2025, which kept it as the leading regional revenue base. The region benefits from the presence of multiple commercially available autonomous AI screening systems, a more established reimbursement pathway for autonomous retinal screening, and stronger provider familiarity with primary care-based diabetic eye screening workflows. The United States remained the center of regional demand because the rollout is extending beyond large academic centers into community and federally qualified health settings. A Utah deployment reported in November 2025 found that around 1 in 4 screened diabetes patients required urgent ophthalmology referral within 3 months, which supports the practical screening value of scaled primary care use. Europe ranked as the second-largest regional market, with 13 CE-certified AI diabetic retinopathy systems in commercial deployment as of 2026.^{[4]Artificial Intelligence-Based Medical Devices for Diabetic Retinopathy Screening in the European Union}

Germany, the United Kingdom, and France have remained the leading European adoption centers. The United Kingdom also contributed early teleophthalmology evidence through the HERMES trial, which helped support broader confidence in remote retinal triage. Europe still faces a slower operating environment than North America because cross-border data governance and retraining requirements are becoming more demanding under newer regulatory rules. That means Europe remains important in the AI-driven retinal screening device market, but growth can be more dependent on regulatory navigation and local deployment design.

Asia-Pacific is forecast to grow at 25.67% CAGR through 2031, which makes it the fastest-growing region in the AI-driven retinal screening device market. The region combines very large diabetes populations, specialist shortages, and active healthcare digitization programs. China remains central because regulators are formalizing dataset expectations for diabetic retinopathy AI, while providers are using AI to scale screening beyond specialist-heavy hospital models. India is also important because it combines a very high diabetes burden with a visible local vendor base and persistent ophthalmologist shortages.